欧洲系统性硬化症患者需肾脏替代治疗的特征与结局:ERA-EDTA登记研究
基于欧洲19个肾脏登记库2002-2013年数据,342例因系统性硬化症导致终末期肾病(ESRD)接受肾脏替代治疗(RRT)的患者纳入研究。结果显示硬化症组RRT依赖恢复率高于糖尿病及其他病因对照组,但透析患者生存率更低,而移植后患者及移植物生存与对照组无差异。
要点
- 硬化症所致ESRD接受RRT者透析期间死亡率高于糖尿病及其他病因对照组。
- 硬化症患者RRT依赖恢复率高于对照组,但恢复所需时间更长。
- 硬化症患者移植后患者及移植物生存与对照组无显著差异。
核心结论
- 透析超过90天的硬化症患者生存率低于其他病因ESRD患者。
- 移植后生存率与其他病因ESRD患者相似。
- 硬化症患者RRT依赖恢复率高于对照组。
研究设计与样本
- 登记研究分析发病率与患病率,并采用匹配队列研究比较临床结局。
- 数据来自2002至2013年向ERA-EDTA登记库提供数据的19个肾脏登记库。
- 共纳入342例以硬化症为ESRD病因的患者,占所有新发RRT患者的0.14%。
- 患者与无硬化症的年龄性别匹配对照组比较,对照组分别为糖尿病所致ESRD和其他非糖尿病病因ESRD。
主要发现
- 2002至2013年,调整后年发病率范围为0.11至0.26/百万人口,患病率范围为0.73至0.95/百万人口。
- 硬化症组独立肾功能恢复率为7.6%,糖尿病对照组为0.7%,其他原发肾病对照组为2.0%,两组比较P均<0.001。
- 自RRT第91天起5年生存概率为38.9%(95%CI 32.0%-45.8%)。
- 移植后5年患者生存率为88.2%(95%CI 75.3%-94.6%),5年移植物生存率为72.4%(95%CI 55.0%-84.0%)。
- 自RRT第91天起调整后死亡率硬化症组高于两对照组,HR分别为1.25(95%CI 1.05-1.48)和2.00(95%CI 1.69-2.39)。
临床怎么用
- 硬化症所致ESRD透析患者需关注较高死亡风险,移植后结局与其他病因ESRD相似。
- 硬化症患者RRT依赖恢复率较高但恢复时间较长,需个体化评估透析撤离时机。
局限性
- 缺乏肾外表现、治疗及复发数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Data for outcomes of patients with end-stage renal disease (ESRD) secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) are limited. We examined the incidence and prevalence of ESRD due to scleroderma in Europe and the outcomes among these patients following initiation of RRT. STUDY DESIGN: Registry study of incidence and prevalence and a matched cohort study of clinical outcomes. SETTING & PARTICIPANTS: Patients represented in any of 19 renal registries that provided data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry between 2002 and 2013. PREDICTOR: Scleroderma as the identified cause of ESRD. OUTCOMES: Incidence and prevalence of ESRD from scleroderma. Recovery from RRT dependence, patient survival after ESRD, and graft survival after kidney transplantation. ANALYTICAL APPROACH: Incidence and prevalence were calculated using population data from the European Union and standardized to population characteristics in 2005. Patient and graft survival were compared with 2 age- and sex-matched control groups without scleroderma: (1) diabetes mellitus as the cause of ESRD and (2) conditions other than diabetes mellitus as the cause of ESRD. Survival analyses were performed using Kaplan-Meier analysis and Cox regression. RESULTS: 342 patients with scleroderma (0.14% of all incident RRT patients) were included. Between 2002 and 2013, the range of adjusted annual incidence and prevalence rates of RRT for ESRD due to scleroderma were 0.11 to 0.26 and 0.73 to 0.95 per million population, respectively. Recovery of independent kidney function was greatest in the scleroderma group (7.6% vs 0.7% in diabetes mellitus and 2.0% in other primary kidney diseases control group patients, both P<0.001), though time required to achieve recovery was longer. The 5-year survival probability from day 91 of RRT among patients with scleroderma was 38.9% (95% CI, 32.0%-45.8%), whereas 5-year posttransplantation patient survival and 5-year allograft survival were 88.2% (95% CI, 75.3%-94.6%) and 72.4% (95% CI, 55.0%-84.0%), respectively. Adjusted mortality from day 91 on RRT was higher among patients with scleroderma than observed in both control groups (HRs of 1.25 [95% CI, 1.05-1.48] and 2.00 [95% CI, 1.69-2.39]). In contrast, patient and graft survival after kidney transplantation did not differ between patients with scleroderma and control groups. LIMITATIONS: No data for extrarenal manifestations, treatment, or recurrence. CONCLUSIONS: Survival of patients with scleroderma who receive dialysis for more than 90 days was worse than for those with other causes of ESRD. Patient survival after transplantation was similar to that observed among patients with ESRD due to other conditions. Patients with scleroderma had a higher rate of recovery from RRT dependence than controls.
引用
- Hruskova Z, Pippias M, Stel VS, et al. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry. Am J Kidney Dis. 2018. PMID: 30122544. doi:10.1053/j.ajkd.2018.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。